BRCA1/2 mutations are identified in approximately 10% of breast cancers (Nik‐Zainal et al., 2016) and 8%–13% of all ovarian cancer cases (Liu et al., 2012). This evidence concerns the gene BRCA1 and ovarian carcinoma.